If you or a loved one has just been diagnosed with atopic dermatitis (eczema), you may be learning about what triggers to avoid so you don’t experience a flare-up. Certain things can trigger ...

Often thought of as simple redness of the skin, eczema is a chronic inflammatory skin condition that most often results in ...

POD is an inflammatory skin disease, appearing as erythematous papules, vesicles, or pustules localized around the mouth, nose, and eyes ... seborrheic dermatitis, or acne vulgaris.

Contact dermatitis presents as a red, scaly, and crusted dermatitis that occurs around the mouth due to allergies to lip cosmetics, food, dental appliances, and musical instruments. It is ...

Share on Pinterest A newly approved drug for the treatment of atopic dermatitis could make a big ... Among the common side effects of EBGLYSS were eye and eyelid inflammation, including redness ...

People with moderate to severe atopic dermatitis (a type of eczema ... or if you have been around someone who has had a serious infection such as tuberculosis (TB). You should also let them ...

Pfizer says the drugs seem to have an impact on itch – often cited as the most bothersome symptom in atopic dermatitis. Aurion Biotech has launched its cell therapy Vyznova for serious eye ...

The FDA has approved Ebglyss (lebrikizumab-lbkz), a new biologic treatment for moderate-to-severe atopic dermatitis in people ...

Goblin is a special girl. Even though she pretty much walks around all the time in her birthday suit. The puppy is currently ...

VTAMA cream is a novel, non-steroidal topical therapy approved for treatment of plaque psoriasis in adults and is under FDA review for an ...

s (ARQT) ZORYVE cream 0.15% provided consistent and meaningful improvements in signs and symptoms of atopic dermatitis in individuals regardless of race, ethnicity, and Fitzpatrick skin types ...

EBGLYSS provides a new first-line biologic treatment for moderate-to-severe atopic dermatitis that is not well controlled with topicals Patients treated with EBGLYSS experienced significant skin ...